Related Experiment Videos

Plasma lecithin-cholesterol acyltransferase activities in uraemic patients

Insights

Plasma lecithin-cholesterol acyltransferase (LCAT) activity is reduced in dialysis patients. Heparin temporarily inhibits LCAT by increasing free fatty acids, with levels returning post-dialysis.

Area of Science:

  • Nephrology
  • Biochemistry
  • Lipid Metabolism

Background:

  • Plasma lecithin-cholesterol acyltransferase (LCAT) plays a crucial role in reverse cholesterol transport.
  • Patients undergoing chronic dialysis often exhibit dyslipidemia, but the underlying mechanisms are not fully understood.

Purpose of the Study:

  • To investigate plasma LCAT activity in patients on hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD).
  • To examine the effect of heparin administration on LCAT activity in dialysis patients and healthy subjects.

Main Methods:

  • LCAT activity was measured in 43 HD patients, 15 CAPD patients, and 19 healthy controls.
  • The impact of intravenous heparin (100 U/kg) on LCAT activity was assessed before, during, and after hemodialysis sessions.

Main Results:

  • LCAT activity was significantly lower in both HD and CAPD patients compared to normal subjects.
  • Heparin administration inhibited LCAT activity, correlating with increased plasma free fatty acids.
  • LCAT inhibition persisted throughout dialysis, returning to baseline levels one hour post-dialysis.

Conclusions:

  • Dialysis patients exhibit reduced plasma LCAT activity, independent of other biochemical parameters studied.
  • Heparin-induced LCAT inhibition is a transient effect linked to elevated free fatty acids.
  • The precise cause of low LCAT in uremic plasma requires further investigation, but uraemic inhibitors are unlikely.

Related Concept Videos